Relief Therapeutics

Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company was founded in 2013 and currently holds a patent for RLF-100, a synthetic form of a natural peptide that protects the lung. It was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
In the wake of the COVID-19 pandemic, scientists at Relief conducted initial studies into the efficacy of RLF-100 in treating severe COVID-19 patients. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19. In September 2020, Relief partnered with US-Israeli firm NeuroRX, who submitted a request for an Emergency Use Authorization to the US FDA for its use in patients in intensive care. 